Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The Novo Nordisk Foundation (NNF ... Another differentiator is the NIVI’s novel structure, combining a state-of-the-art research centre with a limited liability company, according to the ...

Novo Nordisk A/S (NYSE ... is well-positioned to maintain a duopolistic structure for years to come, given the complexity of manufacturing, differentiated intellectual property and brand strength.

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

[CNBC] Microsoft says 394,000 Windows computers infected by Lumma malware globally Microsoft said Wednesday that it broke ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...